Edmp Inc. Has $2.40 Million Position in Cencora, Inc. (NYSE:COR)

Edmp Inc. cut its position in shares of Cencora, Inc. (NYSE:COR) by 1.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,663 shares of the company’s stock after selling 149 shares during the quarter. Cencora accounts for 2.3% of Edmp Inc.’s portfolio, making the stock its 12th biggest holding. Edmp Inc.’s holdings in Cencora were worth $2,396,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in COR. Concord Wealth Partners acquired a new stake in shares of Cencora during the 3rd quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC raised its stake in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after acquiring an additional 69 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Cencora in the 3rd quarter worth approximately $41,000. Modus Advisors LLC bought a new stake in Cencora during the 4th quarter worth approximately $54,000. Finally, Carolina Wealth Advisors LLC increased its holdings in Cencora by 366.7% during the 3rd quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $60,000 after purchasing an additional 209 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Down 0.7 %

Cencora stock opened at $246.25 on Tuesday. The firm has a market capitalization of $47.59 billion, a price-to-earnings ratio of 35.03, a PEG ratio of 1.49 and a beta of 0.49. The company’s 50 day simple moving average is $238.94 and its 200 day simple moving average is $236.90. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.53. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.36 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a $0.55 dividend. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s dividend payout ratio is presently 31.29%.

Wall Street Analyst Weigh In

COR has been the topic of a number of recent analyst reports. Barclays boosted their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Robert W. Baird upped their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Evercore ISI raised their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Finally, Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now owns 306,752 shares of the company’s stock, valued at $74,283,064.32. The trade was a 6.55 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,187 shares of company stock worth $17,790,912. Company insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.